Stock Price Movement and Market Context
On 12 Jan 2026, Epigral Ltd’s share price touched a new 52-week low of Rs.1110, following six consecutive days of decline. The stock demonstrated some resilience during the trading session, reaching an intraday high of Rs.1155.6, a 3.31% gain from its low point. This intraday bounce resulted in a day change of +3.34%, outperforming its sector by 3.88%. However, the overall trend remains bearish as the stock continues to trade below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.
In contrast, the broader market showed signs of recovery. The Sensex, after opening 140.93 points lower, rebounded by 193.39 points to close at 83,628.70, a marginal gain of 0.06%. The index remains 3.03% shy of its 52-week high of 86,159.02. Mega-cap stocks led the market’s modest gains, while the Sensex trades below its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a mixed technical backdrop.
Long-Term Price Performance and Relative Comparison
Over the past year, Epigral Ltd’s stock has declined by 33.96%, a stark contrast to the Sensex’s positive return of 8.04% during the same period. The stock’s 52-week high was Rs.2114.3, underscoring the extent of the recent price erosion. This underperformance extends beyond the last year, with the stock lagging the BSE500 index across one-year, three-month, and three-year timeframes.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Financial Performance and Profitability Metrics
Epigral Ltd’s financial results have reflected subdued growth and profitability pressures. The company’s operating profit has declined at an annualised rate of 5.49% over the last five years, indicating challenges in sustaining long-term earnings momentum. The latest quarterly results for September 2025 revealed a significant contraction in profitability, with the Profit After Tax (PAT) falling by 52.6% to Rs.51.22 crores compared to the previous four-quarter average.
Interest expenses have surged sharply, with the latest six-month figure rising by 286.41% to Rs.45.21 crores, exerting additional pressure on net earnings. The operating profit to net sales ratio for the quarter stood at a low 22.53%, highlighting margin compression in the company’s core operations.
Valuation and Efficiency Indicators
Despite the recent setbacks, Epigral Ltd exhibits certain strengths in operational efficiency and valuation metrics. The company maintains a high Return on Capital Employed (ROCE) of 23.19%, reflecting effective utilisation of capital resources. Its debt servicing capability remains robust, with a Debt to EBITDA ratio of 1.34 times, indicating manageable leverage levels.
Valuation metrics suggest the stock is trading at a discount relative to its peers’ historical averages. The Enterprise Value to Capital Employed ratio stands at a moderate 2.1, while the company’s ROCE of 19.3% further supports its attractive valuation profile. Over the past year, profits have increased by 37.1%, even as the stock price declined, resulting in a low PEG ratio of 0.4.
Shareholding and Market Sentiment
The majority shareholding in Epigral Ltd is held by promoters, indicating concentrated ownership. The company’s Mojo Score currently stands at 31.0, with a Mojo Grade of Sell, an improvement from a previous Strong Sell rating assigned on 26 Dec 2025. The Market Capitalisation Grade is rated at 3, reflecting its small-cap status within the Specialty Chemicals sector.
Considering Epigral Ltd? Wait! SwitchER has found potentially better options in Specialty Chemicals and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Specialty Chemicals + beyond scope
- - Top-rated alternatives ready
Technical and Trend Analysis
The stock’s current trading below all major moving averages signals a sustained downtrend. The recent six-day decline culminating in the 52-week low suggests persistent selling pressure. However, the intraday recovery on 12 Jan 2026 indicates some short-term buying interest, though the overall technical picture remains cautious.
Sector and Market Positioning
Operating within the Specialty Chemicals sector, Epigral Ltd faces competitive pressures and market dynamics that have influenced its performance. While the broader market and mega-cap stocks have shown resilience, Epigral’s small-cap status and recent financial results have contributed to its relative underperformance.
Summary of Key Metrics
To summarise, Epigral Ltd’s stock has declined by nearly one-third over the past year, reaching a new 52-week low of Rs.1110. The company’s financial indicators reveal a mixed picture, with declining profitability and rising interest costs offset by strong capital efficiency and manageable debt levels. The stock’s valuation metrics suggest it is trading at a discount compared to peers, though the prevailing downtrend and recent results have weighed on investor sentiment.
Market participants will note the stock’s Mojo Grade upgrade from Strong Sell to Sell as of late December 2025, reflecting a modest improvement in outlook. Nonetheless, the company’s performance remains below sector and market benchmarks, underscoring the challenges faced in regaining upward momentum.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
